StockData
Bicycle Therapeutics PLC logo

Bicycle Therapeutics PLC (BCYC) company profile

BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 11/3080% below fair value
$3.20+0.02 (+0.63%)

Close on Nov 17, 2026Market cap $224.30MP/E –Yield 0.00%

About Bicycle Therapeutics

Pharmaceutical Preparations, SIC 2834

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing synthetic bicyclic peptides, termed Bicycle molecules, to treat diseases with significant unmet medical need. The company utilizes a proprietary phage display screening platform to discover and engineer therapeutics across multiple drug modalities, including drug conjugates, radioconjugates, imaging agents, and immune cell agonists. Its primary internal pipeline centers on oncology, led by product candidates such as nuzefatide pevedotin and the radiopharmaceutical BT1702. In addition to internal discovery, the company collaborates with external biopharmaceutical partners to develop therapies across various disease indications, including cardiometabolic, central nervous system, and neuromuscular conditions.

The company operates internationally, maintaining an intellectual property portfolio that spans ten distinct territories: the United Kingdom, the European Union, the United States, Japan, Hong Kong, Australia, China, Israel, Switzerland, and Norway. Research activities and clinical collaborations are conducted in partnership with leading global institutions, such as the German Cancer Research Center and Universitätsmedizin Essen. The provided text does not identify the location of the company's headquarters.

Summary of the business section of Bicycle Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Bicycle Therapeutics PLC
Founded
2009
Headquarters
Cambridge, X0
Address
Blocks A & B, Portway Building, Granta Park, Great Abington CB21 6GS
Phone
011441223261503
Employees
288, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
X0
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Cambridge, United Kingdom

Stock & identifiers

Ticker
BCYC
Exchange
Nasdaq
IPO date
May 23, 2019
Shares outstanding
70M, Oct 26, 2026
Public float
$266.67M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1761612
CUSIP
088786108
ISIN
US0887861088
FIGI
BBG00P0YWPK6
Share class FIGI
BBG00P0YWQ97
LEI
213800XKUI6R7GKC3E43
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Kevin LeeCHIEF EXECUTIVE OFFICER, Director595,866
Jennifer Scott PerryChief Operating Officer89,602
Michael SkynnerCHIEF SCIENTIFIC OFFICER154,726
Michael Charles Ferguson HannayCHIEF PROD & SUPPLY CHAIN OFF92,561
Travis Alvin ThompsonChief Financial Officer64,449
Alistair MilnesCHIEF OPERATING OFFICER136,717
Alethia YoungChief Financial Officer88,959
Eric WestinChief Medical Officer2,305
Nigel CrockettCHIEF BUSINESS OFFICER51,053
Santiago ArroyoCHIEF DEVELOPMENT OFFICER69,057
Robert Charles SwantonDirector15,782
Roger D. DanseyDirector15,532
Stephen H. SandsDirector26,893
Jose-Carlos Gutierrez-RamosDirector32,500
Bros. Advisors Lp BakerDirector918,483
Julian BakerDirector–
Felix BakerDirector937,483
Brothers Life Sciences LP BakerDirector579,856
Bros. Advisors (GP) LLC BakerDirector9,995,274
667, L.P.Director787,954
Herve HoppenotDirector15,532
Gregory Paul WinterDirector196,427
Janice BourqueDirector32,500
Alessandro RivaDirector19,880
Pierre LegaultDirector46,000

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$6.34M$1.93M$2.31M$24–
FY2024$4.86M$3.33M$2.26M$47–
FY2023$5.54M$625.07K$2.78M$61–
FY2022$8.63M-$6.36M$4.04M$165$89
FY2021$4.47M$25.67M$1.74M$339$99

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Kevin Lee
Chief Executive Officer
$862.34K$1.72M$2.96M$543.64K$249.40K$6.34M+31%
Michael Skynner
Chief Scientific Officer
$612.47K$490.00K$836.47K$319.36K$68.71K$2.33M–
Alistair Milnes
Chief Corporate Development Officer
$578.19K$490.00K$836.47K$322.52K$65.25K$2.29M-12%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 23, 2019
Offer price
$14.00
Securities offered
4,333,333
Gross proceeds
$60.67M
Exchange
Nasdaq
First trading day
May 23, 2019
First-day close
$12.00-14.3%
Lock-up ends (est.)
Nov 19, 2019

“The initial public offering price per ADS is $14.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 288 full-time or part-time employees, including 108 with M.D.”

Corporate history

Events identified from SEC filings

DateEventDetails
May 24, 2019Name changeName changed from BICYCLE THERAPEUTICS Ltd to Bicycle Therapeutics PLC
May 23, 2019IPOInitial public offering priced (424B4 prospectus)
May 20, 2019ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?